Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BC-U001 in rheumatoid arthritis
NCT04971980Phase 2Active, not recruiting
- Sponsor
- Baylx
- Start
- Apr 2021
- Primary completion
- Jul 2023
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BX-U001 in rheumatoid arthritis (RA), sponsored by Baylx. Primary endpoints: Adverse Events at 28 days, Vital Signs at 28 days and 6 more. Started Apr 2021; status: active, not recruiting.
02
Drugs
BX-U001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT04971980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04971980.